Results 41 to 50 of about 9,514 (200)
Advanced Science, EarlyView.In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu +12 more
wiley +1 more source
Circulating monocyte partitioning and its alteration in hematological chronic neoplasms
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi +4 more
wiley +1 more source
Hypomethylating agents use in acute myeloid leukemia: A single-center experience
Indian Journal of Medical and Paediatric Oncology, 2020 Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors.
Sravan Kumar Bodepudi +5 more
doaj +1 more source
Nature Communications, 2023 Hypomethylating agents, such as 5-Azacytidine (5-AZA), are standard of care for patients with myelodysplastic and myeloid malignancies, however response rates are limited and risk of relapses high.
Qingyu Xu +31 more
doaj +1 more source
Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency [PDF]
Clinical Lymphoma Myeloma and Leukemia, 2010 To our knowledge, the feasibility of therapy with hypomethylating agents (HAs) in patients with renal insufficiency (RI) has not been examined.We reviewed 41 patients with a diagnosis of acute myeloid leukemia (n = 17), myelodysplastic syndromes (n = 15), and chronic myelomonocytic leukemia (n = 9) who had RI and were receiving therapy with azacitidine
G Nicolas, Batty +10 more
openaire +2 more sources
International Journal of Cancer, EarlyView.ABSTRACT Wilms Tumour (WT), the most common kidney cancer in children, presents features of altered kidney development and frequently exhibits molecular alterations at the 11p15.5 imprinted locus, affecting the IGF2 and H19 genes, which contribute to tumour growth and predisposition.
Abu Saadat +14 more
wiley +1 more source
Case Reports in Hematology, 2021 Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using ...
Di Wu +3 more
doaj +1 more source
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes [PDF]
Current Opinion in Hematology, 2014 Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis.
Amer M, Zeidan +2 more
openaire +2 more sources
Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials
iNew Medicine, EarlyView.ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong +5 more
wiley +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki +6 more
wiley +1 more source